linjc16/ctgov huggingface dataset:
The Nutrition Care in Canadian Hospitals Study; 2010-2013.

Study Overview
=================
Brief Summary
-----------------
The Nutrition Care In Canadian Hospitals study, conducted by the Canadian Malnutrition Task Force had the primary purpose of determining the prevalence of malnutrition in Canadian acute care hospitals. Secondary objectives were to determine the independent association of malnutrition with patient centred outcomes (e.g. length of stay) and describe the nutrition care processes for malnourished and well nourished patients.

Detailed Description
-----------------
Data from 18 community and academic hospitals was collected from a convenience sample of 1022 medical or surgical patients. This prospective cohort study followed patients throughout their admission to 30-day post discharge. Measures included nutrition indicators, nutrition care processes and health outcomes.

Official Title
-----------------
The Nutrition Care In Canadian Hospitals Study: 2010-2013

Conditions
-----------------
Malnutrition

Intervention / Treatment
-----------------
* Other: There was no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute care admission, medical or surgical unit; English or French language;anticipated to stay in hospital for 2 or more days; consent to study entry; Exclusion Criteria: other hospital units; palliative patients; unable to complete informed consent due to language barrier or no proxy available; dementia -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| medica/surgical<br>Medical or surgical patients from 18 hospitals | Other: There was no intervention<br>* observational study, no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay | length of stay in acute care bed | 0- 60 days |
Effect of Colostrum on Gut Permeability and Endotoxin Level in Chronic Alcoholic Disease

Study Overview
=================
Brief Summary
-----------------
Chronic alcohol ingestion is related with leaky gut syndrome. Colostrum is well-studied that it has a effect of decreasing the degree of leaky gut syndrome. So the investigators are planning to find out whether Colostrum has a effect of decreasing the degree of leaky gut syndrome.

Detailed Description
-----------------
We randomly sort the participant as placebo group and colostrum group. Each group consists of 17 people. and the duration of our study for one participant is 3 weeks. (Participant takes colostrum for 3 weeks.) When a person gets leaky gut syndrome, his or her endotoxin and lactulose/mannitol ratio (L/M ratio, in urine) can elevate. So We will compare the value of those two parameters and LFT. etc. after the administration of colostrum or placebo.

Official Title
-----------------
Effect of Colostrum Administration on Improving Gut Permeability and Serum Endotoxin Level in Chronic Alcohol Drinkers With Hepatic Dysfunction

Conditions
-----------------
Leaky Gut Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: colostrum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men aged over 20 who's alcohol consumption per day is 20.0gram average He must agree to participate this trial voluntarily. Liver function test within 3 months : AST more than 30 or ALT more than 33 or Gamma-GT more than 46 Men who have result of Ultra-sono result of abdomen without Liver cirrhosis Exclusion Criteria: Hepatitis B or C , liver cirrhosis patient Men who have undergo bowel operation Men who are taking NSAIDs Periodontitis or GERD or other G-I tract infection within 2 weeks before enrollment Men who have been given anticancer drug within one year Men who have been given antibiotics within 2 weeks Creatinine level >= 1.4mg/dl Men who are taking G-I motility drugs or anti-ulcer drug Milk allergy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Colostrum<br> | Dietary Supplement: colostrum<br>* colostrum, 2g, 2 times a day, for 3 weeks<br>* Other names: Mucoba;|
| No Intervention: Sugar pill<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endotoxin |  | 1st visit and 3 weeks after 1st visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lactulose/mannitol ratio |  | 3 weeks |
Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker

Study Overview
=================
Brief Summary
-----------------
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm which originates from an incomplete process of differentiation of the hematopoietic stem cells (HSCs) to the adult cells which lead to accumulation of their immature form into the BM and the peripheral blood. It is characterized by the reciprocal translocation. The resulting oncoprotein, BCR/ABL1, is considered essential for the initiation and manifestation of the disease . In CML, leukemic stem cell (LSC) supposedly resides within the CD45+/ CD34+/CD38-/Lin- fraction of the leukemic clone (3). However, normal hematopoietic SC also exhibit this phenotype so that additional markers are required to discriminate CML LSC from normal SC. CD34+/CD38-/Lin- CML LSC specifically co-express dipeptidylpeptidase IV(DPPIV=CD26). This enzyme disrupts LSC-niche interactions by degrading stroma derived factor-1 (SDF-1). Moreover, CD26 is a robust biomarker for the quantification and isolation of CML LSC (4). It was reported that CD26+ LSCs were significantly correlated with BCR-ABL1 transcript level at diagnosis and after three months of treatment with tyrosine kinase inhibitor (TKI) .

Official Title
-----------------
Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker

Conditions
-----------------
Chronic Myeloid Leukemia, Chronic Phase

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: : All suspected patients for CML diagnosis aged more than 18 years who presented with high white blood cells(WBCs) count , marked shift to left in peripheral blood with or without splenomegaly . Exclusion Criteria: Patients on treatment or presence of blasts in peripheral blood sample.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peripheral Blood Dipeptidylpeptidase IV (CD26) | to detect CD26+ LSCs by flow cytometry for accurate diagnosis of CML patients from peripheral blood sample to reduce the need for Bone Marrow aspiration. | 1 year |
Longitudinal Study of Biomarkers

Study Overview
=================
Brief Summary
-----------------
Biomarkers are small molecules that can be detected in the body fluids of patients; they often correlate with the presence of a cancer. MicroRNAs and proteins are small molecules which have recently been discovered in cells. They are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer. Many previous studies have been done evaluating the expression of microRNAs and proteins in normal tissues as well as a wide variety of cancers. Recently, microRNAs and proteins from tumor cells have been detected circulating in the blood of patients with cancer. This presents a novel opportunity to use microRNAs and proteins in the blood as an early predictor of cancer as well as a marker of response to therapy. Previous work in our labs have identified miRNAs and proteins in the blood and cerebrospinal fluid (CSF) of pediatric patients with brain tumors. To determine a longitudinal evaluation of the presence of microRNAs and proteins in the blood, cerebrospinal fluid and urine of patients with central nervous system tumors from diagnosis through the course of their treatment. Though the duration of active treatment varies significantly based upon the diagnosis, patients will be followed for up to 24 months after enrollment onto the study).

Official Title
-----------------
A Longitudinal Study of Biomarkers in Pediatric Patients With Central Nervous System Tumors

Conditions
-----------------
Central Nervous System Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ages 1 day to 21 years Patients with radiographically and/or histologically confirmed CNS tumors treated at Children's Memorial Hospital and Lurie Children's Hospital in Chicago Patients must be newly diagnosed and have had no prior anticancer therapy (except surgery) for their current diagnosis. The use of steroids is permissible. Patients and/or parents/legal guardians must have signed an informed consent and assent when applicable. Exclusion Criteria: Patients who have completed treatment and do not require routine blood draws and/or lumbar punctures Patients who are considered too ill to participate as determined by their treating physician Patients who are pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Central Nervous System Tumors<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of microRNAs and proteins in the blood, cerebrospinal fluid and urine of patients with central nervous system tumors from diagnosis through the course of their treatment |  | 24 months |
Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

Official Title
-----------------
An Open-label, Randomized, Cross-over, Multiple Dose, Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of DA-5207 Transdermal Delivery System in Healthy Adults

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Aricept 5mg Tablet
* Drug: Aricept 10mg Tablet
* Drug: DA-5207 A
* Drug: DA-5207 B


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health Volunteers (Age: 19 55 years) Body Weight: Male≥55kg, Female≥50kg 18.5 ≤BMI≤ 25.0 Exclusion Criteria: Galactose intolerance, Lapp lactase deficiency, Glucose-galactose malabsorption Allergy or Drug hypersensitivity Clinically significant Medical History AST, ALT>Upper Normal Range*1.25, eGFR<60mL/min/1.73m² Heavy caffeine intake Heavy alcohol intake (more than 210g/week) Heavy smoker (more than 10 cigarettes/day)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence 1<br>Period 1, Aricept 5mg → DA-5207 A; Period 2, Aricept 5mg → Aricept 10mg | Drug: Aricept 5mg Tablet<br>* 1 tablet once daily<br>Drug: Aricept 10mg Tablet<br>* 1 tablet once daily<br>Drug: DA-5207 A<br>* 1 patch once weekly<br>|
| Experimental: Sequence 2<br>Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 A | Drug: Aricept 5mg Tablet<br>* 1 tablet once daily<br>Drug: Aricept 10mg Tablet<br>* 1 tablet once daily<br>Drug: DA-5207 A<br>* 1 patch once weekly<br>|
| Experimental: Sequence 3<br>Period 1, Aricept 5mg → DA-5207 B; Period 2, Aricept 5mg → Aricept 10mg | Drug: Aricept 5mg Tablet<br>* 1 tablet once daily<br>Drug: Aricept 10mg Tablet<br>* 1 tablet once daily<br>Drug: DA-5207 B<br>* 1 patch once weekly<br>|
| Experimental: Sequence 4<br>Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 B | Drug: Aricept 5mg Tablet<br>* 1 tablet once daily<br>Drug: Aricept 10mg Tablet<br>* 1 tablet once daily<br>Drug: DA-5207 B<br>* 1 patch once weekly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC | area under the concentration-time curve | 29-36 days | 
| Css,max | maximum serum concentration at steady state | 0-36 days |
DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determinate the prevalence of moderate dehydration among children aged 9 to 11 who are going to school.

Detailed Description
-----------------
Many children have a limited caloric intake at the breakfast with a limited amount of water intake. There is no data about the prevalence of dehydration in children who are regularly going to school in France.

Official Title
-----------------
DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children.

Conditions
-----------------
Dehydration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy child aged 9 to 11 years old. Exclusion Criteria: Individual with illness Individual with past history of gut or metabolic diseases Past history of renal disease. Child whom parents decline to participate

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| dosage of the urinary osmolality<br>dosage of the urinary osmolality | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of dehydration (as defined as urinary osmolality > 800 mOsmol/l) Osmolality is measured by freezing point depression | Prevalence of dehydration (as defined as urinary osmolality > 800 mOsmol/l) Osmolality is measured by freezing point depression | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of water intake at breakfast | To determine whether urinary osmolality is correlated to total water intake at breakfast | Day 1 | 
| Total energy and nutrient intake | To determine whether urinary osmolality is correlated to nutrient and energy intake at breakfast. | Day 1 |
Noise in Critical Care Units.Impact on Critically Ill Patients and Healthcare Personnel

Study Overview
=================
Brief Summary
-----------------
Study noise level in the ICU and its effect on both patients and healthcare personnel. Use music and study same effects on same patients and healthcare personnel.

Detailed Description
-----------------
Level of noise is measured and investigate its effects on delirium prevalence. sleep quality score. hemodynamics of patients. burnout and depressive symptoms of healthcare personnel

Official Title
-----------------
Noise in Critical Care Units.Impact on Critically Ill Patients and Healthcare Personnel

Conditions
-----------------
Noise; Adverse Effect

Intervention / Treatment
-----------------
* Other: music


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients admitted to ICU fully conscious and can answer the questionnaires of the study Exclusion Criteria: confused patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Music exposure<br>will be exposed to music to investigate effects on preventing noise Adverse effects | Other: music<br>* exposure to music to investigate its effects on reducing noise adverse effects<br>|
| No Intervention: Control<br>no exposure to music | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sleep quality: Richard Campbell sleep questionnaire | Richard Campbell sleep questionnaire will be used A modified 6 question questionnaire each question from 0 to 100 | 1 month | 
| delirium | Confusion Assessment Method flow sheet in ICU (CAM -ICU too)l will be used 4 questions flow sheet | in hospital up to 2 months | 
| Burnout syndrome | Occurrence of burnout syndrome in healthcare personnel | 1 month | 
| Depression symptoms | Occurrence of depression symptoms in healthcare personnel assessed by becks tool | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay in icu | Length of patient stay in the ICU | in hospital 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Noise ICU, delirium, depression, burnout, music
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Study Overview
=================
Brief Summary
-----------------
The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.

Official Title
-----------------
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.

Conditions
-----------------
Japanese Encephalitis

Intervention / Treatment
-----------------
* Biological: IC51


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: Healthy adults who completed the primary immunization in study IC51 309 Male and female healthy subjects aged at least 18 years with written informed consent and either no childbearing potential or negative pregnancy test Main Exclusion Criteria: • History of immunodeficiency or immunosuppressive therapy, known Human Immunodeficiency Virus (HIV), or drug addiction including alcohol dependence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br> | Biological: IC51<br>* IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seroconversion Rate |  | at Month 12 after booster | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and Adverse Events |  | up to Month 12 after booster | 
| Seroconversion |  | at D28 and Month 6 after booster | 
| Geometric Mean Titer |  | D28, Month 6 and Month 12 after booster |
Motor Imagery and Action Observation on Motor Learning

Study Overview
=================
Brief Summary
-----------------
This study evaluates the influence of motor imagery and action observation on motor learning

Official Title
-----------------
Assessment of the Effects of Motor Imagery and Action Observation on Motor Learning in Healthy Subjects: a Randomized Controlled Trial

Conditions
-----------------
Motor Learning

Intervention / Treatment
-----------------
* Behavioral: Motor imagery
* Behavioral: Double time motor imagery
* Behavioral: Action observation
* Behavioral: Placebo intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: asymptomatic subjects men and women between 18 and 65 years of age participants with no systemic, neurological, cognitive or psychological disease. Exclusion Criteria: underage participants presence of systemic pathology, pain and/or weakness that prevents the protocol participants who have undergone an operation in the spine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motor Imagery<br> | Behavioral: Motor imagery<br>* This group will perform motor imagery training on motor learning of different motor tasks<br>|
| Experimental: Double Time Motor Imagery<br> | Behavioral: Double time motor imagery<br>* This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.<br>|
| Experimental: Action observation<br> | Behavioral: Action observation<br>* This group will perform action observation training on motor learning of various motor tasks.<br>|
| Placebo Comparator: Placebo group<br> | Behavioral: Placebo intervention<br>* This group will watch a video of a landscape without the presence of people.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Purdue Pegboard test | This main variable will be composed by the learning of a sequence of digital movements | Change from hit ratio in a manual skill between baseline and 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Motor imagery, Action observation